EF Hutton analyst Tony Butler initiated coverage of Apexigen with a Buy rating and $8 price target. The "recently de-SPACed" biotech is developing sotigalimab as an orthogonal immunoactivating therapy in combination with immune checkpoint inhibitors and chemotherapy against a number of cancer indications, Butler tells investors.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.